Physician

Andrew J Chang, MD

According to 2025 Medicare claims, Andrew Chang, MD (NPI: 1760640791) practices urology in the Raleigh-Cary, NC market, with the plurality of this provider's patient population coming from Wake, NC. This provider's primary affiliated billing organization is ASSOCIATED UROLOGISTS OF NORTH CAROLINA PA (NPI: 1568767002; TIN: 272528143) and primary practice location at 27612-8038.

Chang's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 303 traditional Medicare patients, billed 2,850 HCPCS/CPT codes, and received $123,770 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,017 prescription claims across 309 beneficiaries totaling $145,877 in drug costs, led by Myrbetriq (Mirabegron). DME data shows 23 claims. Open Payments data shows 68 records totaling $1,694. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $98,461 and ending at $123,770. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $41,265 to $145,877. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $111 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	321	2,063	$98,461
2016	472	4,868	$168,065
2017	524	6,801	$218,180
2018	577	5,526	$185,572
2019	696	13,660	$272,190
2020	363	5,899	$146,494
2021	242	4,158	$163,276
2022	327	3,171	$151,030
2023	325	3,194	$611,399
2024	303	2,850	$123,770

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	145	541	$41,265
2016	159	461	$49,353
2017	139	473	$50,305
2018	158	558	$85,183
2019	172	583	$92,126
2020	169	446	$55,355
2021	194	463	$53,088
2022	219	576	$102,999
2023	277	770	$160,036
2024	309	1,017	$145,877

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	25	$6,057
2017	N/R	30	$2,495
2018	N/R	72	$8,277
2019	N/R	55	$8,161
2020	N/R	21	$6,171
2021	N/R	20	$7,019
2022	N/R	53	$18,004
2023	N/R	26	$8,887
2024	N/R	23	$10,091

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	111	152	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	145	212	$63
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	99	122	$13
81001	Manual urinalysis test with examination using microscope, automated	99	167	$3
81003	Automated urinalysis test	159	244	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Myrbetriq	Mirabegron	66	4,938	$71,771
Gemtesa	Vibegron	48	2,538	$39,788
Eliquis	Apixaban	13	390	$7,903
Alfuzosin Hcl Er	Alfuzosin Hcl	221	18,765	$5,378
Solifenacin Succinate	Solifenacin Succinate	53	4,208	$2,227

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
A4351	Intermittent urinary catheter; straight tip, with or without coating (teflon, silicone, silicone elastomer, or hydrophilic, etc.), each	N	N/R	23	$10,091

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	68	$1,694	Dendreon Pharmaceuticals LLC
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Andrew J. Chang, MD?

Tedicare shows public-source Medicare data for Andrew J. Chang, MD (NPI 1760640791), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Andrew J. Chang, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Andrew J. Chang, MD?

Andrew J. Chang, MD is linked to ASSOCIATED UROLOGISTS OF NORTH CAROLINA PA (billing NPI 1568767002) in the available physician profile data.

Does Andrew J. Chang, MD have Open Payments data?

Andrew J. Chang, MD has 68 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.